Physician profile
Nagendra Gupta
NPI 1013221290
$5,078.24
in general payments reported to CMS, 2019-2025
14 companies · $3,538 in 2025
The $3,538 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $148 · 2021: $352 · 2022: $443 · 2023: $101 · 2024: $271 · 2025: $3,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,610 · Food and Beverage: $1,231 · Travel and Lodging: $69.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,609.50 |
| Food and Beverage | $1,230.76 |
| Travel and Lodging | $69.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $3,336.29 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $442.65 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $306.79 | 2019-2022 | |
| Abbvie INC. | $214.65 | 2021-2024 | |
| Vifor Pharma, INC. | $148.12 | 2020-2024 | Veltassa |
| Pfizer INC. | $130.93 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $105.78 | 2021 | |
| Novartis Pharmaceuticals Corporation | $84.26 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $71.16 | 2021-2023 | Zerbaxa, Dificid |
| Astrazeneca Pharmaceuticals LP | $67.78 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.10 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.09 | 2022-2024 | Eliquis |
| Allergan, INC. | $39.46 | 2019-2020 | |
| Stryker Corporation | $28.18 | 2025 | Flowtriever |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nagendra Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.